异甘草酸镁治疗自身免疫性肝炎患者血清细胞因子水平变化*

doi:10.3969/j.issn.1672-5069.2023.02.016

Abstract

Abstract: Objective The purpose of this study was to investigate the efficacy of magnesium isoglycyrrhizinate in the treatment of patients with autoimmune hepatitis (AIH) and the effects on serum cytokine changes. Methods 46 patients with AIH were admitted to the Nantong Cancer Hospital between August 2019 and August 2021, and were randomly divided into two groups, with 23 cases in each. The prednisone was routinely given to all the patients in the two groups, and the dose was gradually tapered to maintaining. The magnesium isoglycyrrhizinate was intravenously administered in patients in observation group for 8 weeks. Serum interleukin 18 (IL-18), IL-2 and tumor necrosis factor alpha (TNF-α) levels were assayed by enzyme-linked immunosorbent assay, serum nitric oxide (NO) level was detected by nitrate reductase method, and serum laminin (LN), hyaluronic acid (HA), type III procollagen (PCIII) and type IV collagen (IV-C) levels were determined by radioimmunoassay. Results At the end of eight week treatment, serum ALT, AST and bilirubin levels in the observation group were (44.3±7.3)U/L, (38.5±6.4)U/L and (25.2±5.2)μmmol/L, all significantly lower than [(69.8±11.3)U/L, (46.5±7.3)U/L and (31.6±6.4)μmmol/L, respectively, P<0.05] in the control; serum IL-18 and TNF-α levels were (36.3±6.3)pg/mL and (27.1±4.4)pg/mL, both significantly lower than [(42.5±7.4)pg/mL and (35.5±5.9)pg/mL, respectively, P<0.05], while serum NO and IL-2 levels were (47.3±7.1)μmmol/L and (464.3±65.2)pg/mL, both significantly higher than [(41.8±8.1)μmmol/L and (419.8±74.1)pg/mL, respectively, P<0.05] in the control; serum HA, PCⅢ and Ⅳ-C levels were (131.7±22.5)μg/L, (133.9±22.6)μg/L and (126.9±19.8)μg/L, all significantly lower than [(184.4±28.4)μg/L, (167.4±28.1)μg/L and (158.6±24.6)μg/L, respectively, P<0.05] in the control. Conclusion The administration of magnesium isoglycyrrhizinate in the treatment of patients with AIH could short-termly improve liver function test normalization and relieve liver fibrosis, which needs further clinical investigation.

Key words: Autoimmune hepatitis, Magnesium isoglycyrrhizinate, Cytokines, Therapy

Ling Jiahui, Ni Meixin, Han Lili, et al.. Serum cytokine changes in patients with autoimmune hepatitis receiving magnesium isoglycyrrhizinate treatment[J]. Journal of Practical Hepatology, 2023, 26(2): 214-217.

References

[1] Pape S, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. Uni Eur Gastroenterol J, 2019, 7(9): 1156-1163.
[2] Liberal R, de Boer YS, Heneghan MA. Established and novel therapeutic options for autoimmune hepatitis. Lancet Gastroenterol Hepatol, 2021, 6(4): 315-326.
[3] Takahashi A, Ohira H. Autoimmune hepatitis, fatty liver, and Fukushima. Fukushima J Med Sci, 2019, 65(2): 25-29.
[4] 李品桦, 刘旭东, 黄露, 等. 非酒精性脂肪性肝病肝纤维化进展与内皮素-1/一氧化氮的关系. 临床肝胆病杂志, 2021, 37(11): 2558-2562.
[5] Tahvildari M, Dana R. Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases. J Immunol, 2019, 203(11): 2749-2755.
[6] Xie C, Li X, Zhu J, et al. Magnesium isoglycyrrhizinate suppresses LPS-induced inflammation and oxidative stress through inhibiting NF-κB and MAPK pathways in RAW264. 7 cells. Bioorg Med Chem, 2019, 27(3): 516-524.
[7] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015). 临床肝胆病杂志, 2016, 32(1): 9-22.
[8] Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the observation of liver diseases. Hepatology, 2020, 72(2): 671-722.
[9] 李变利, 彭颖, 杨柳, 等. 药物诱导性AIH临床特征分析. 中国临床药理学杂志, 2021, 37(17): 2258-2261.
[10] Lohse AW, Sebode M, Jørgensen MH, et al. Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European reference network on hepatological diseases and the international autoimmune hepatitis group. J Hepatol, 2020, 73(6): 1496-1506.
[11] Bischoff S, Yesmembetov K, Antoni C, et al. Autoimmune hepatitis: a review of established and evolving treatments. J Gastrointestin Liver Dis, 2020, 29(3): 429-443.
[12] Halliday N, Dyson JK, Thorburn D, et al. Review article: experimental therapies in autoimmune hepatitis. Aliment Pharmacol Ther, 2020, 52(7): 1134-1149.
[13] Gomes NBN, Torres US, Ferraz MLCG, et al. Autoimmune hepatitis in practice, from diagnosis to complications: what is the role of imaging, a clinicoradiological review. Clin Imaging, 2021, 74(3): 31-40.
[14] Liu Y, Meng X, Wang C, et al. Interleukin-18 plays a positive feedback activity to natural killer-like B cells in hepatitis B virus-associated acute-on-chronic liver failure. Viral Immunol, 2022, 35(1): 50-59.
[15] Ali T, Saxena R, Rani I, et al. Association of interleukin-18 genotypes (-607C>A) and (-137 G>C) with the hepatitis B virus disease progression to hepatocellular carcinoma. Mol Cell Biochem, 2021, 476(11): 3923-3933.
[16] Amirpour-Rostami S, Kazemi Arababadi M. IL-18 and IL-1β gene polymorphisms: the plausible risk factors for chronic hepatitis B. Viral Immunol, 2019, 32(5): 208-213.
[17] 王雨, 王楠, 王巧侠, 等. 利肝隆联合异甘草酸镁治疗AIH患者疗效及其对血清趋化因子水平的影响. 实用肝脏病杂志, 2020, 23(6): 821-824.
[18] Liu L, Cao J, Zhong Z, et al. Noninvasive indicators predict advanced liver fibrosis in autoimmune hepatitis patients. J Clin Lab Anal, 2019, 33(7): 922-931.
[19] Febres-Aldana CA, Alghamdi S, Krishnamurthy K, et al. Liver fibrosis helps to distinguish autoimmune hepatitis from DILI with autoimmune features: a review of twenty cases. J Clin Transl Hepatol, 2019, 7(1): 21-26.
[20] 张曼, 张晓伟, 徐圣秋, 等. 异甘草酸镁对四氯化碳诱导肝损伤大鼠肝组织Bax、Bcl-2蛋白表达及肝纤维化指标影响. 中国医院药学杂志, 2021, 41(12): 1224-1228.
[21] Lu L, Hao K, Hong Y, et al. Magnesium isoglycyrrhizinate reduces hepatic lipotoxicity through regulating metabolic abnormalities. Int J Mol Sci, 2021, 22(11): 5884-5893.
[22] Zhao XJ, Yang YZ, Zheng YJ, et al. Corrigendum to magnesium isoglycyrrhizinate blocks fructose-induced hepatic NF-κB/NLRP3 inflammasome activation and lipid metabolism disorder. Eur J Pharmacol, 2021, 809(1): 141-150.
[23] Liu M, Zheng B, Liu P, et al. Exploration of the hepatoprotective effect and mechanism of magnesium isoglycyrrhizinate in mice with arsenic trioxide induced acute liver injury. Mol Med Rep, 2021, 23(6): 438-449.
[24] Mei F, Yu J, Li M, et al. Magnesium isoglycyrrhizinate alleviates liver injury in obese rats with acute necrotizing pancreatitis. Pathol Res Pract, 2019, 215(1): 106-114.
[25] Zheng B, Yang Y, Li J, et al. Magnesium isoglycyrrhizinate alleviates arsenic trioxide-induced cardiotoxicity: contribution of Nrf2 and TLR4/NF-κB signaling pathway. Drug Des Devel Ther, 2021, 15(2): 543-556.
[26] Yang Q, Zhang P, Liu T, et al. Magnesium isoglycyrrhizinate ameliorates radiation-induced pulmonary fibrosis by inhibiting fibroblast differentiation via the p38MAPK/Akt/Nox4 pathway. Biomed Pharmacother, 2019, 115(4): 1089-1097.
[27] Chen X, Wang X, Yang L, et al. Corrigendum to: Magnesium isoglycyrrhizinate prevents cadmium-induced activation of JNK and apoptotic hepatocyte death by reversing ROS-inactivated PP2A. J Pharm Pharmacol, 2021, 73(12): 1726-1735.
[28] Wang Y, Wang Z, Gao M, et al. Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury: a phase II trial. Liver Int, 2019, 39(11): 2102-2111.
[29] Gao Y, Tian Y, Zhang X, et al. Magnesium isoglycyrrhizinate ameliorates concanavalin A-induced liver injury via the p38 and JNK MAPK pathway. Immunopharmacol Immunotoxicol, 2020, 42(5): 445-455.
[30] Jiang W, Xu S, Guo H, et al. Magnesium isoglycyrrhizinate prevents the nonalcoholic hepatic steatosis via regulating energy homeostasis. J Cell Mol Med, 2020, 24(13): 7201-7213.

Serum cytokine changes in patients with autoimmune hepatitis receiving magnesium isoglycyrrhizinate treatment

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yin Wen, Lu Kexiang, Wang Xue, et al.. Short-term efficacy of oxymatrine and entecavir combination in the treatment of patients with serum HBeAg-positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(2): 173-176.
[2]	Wei Li, Liu Bo, Zhao Nan, et al.. Would the coincidence of nonalcoholic fatty liver diseases impact the antiviral response to enticavir therapy in patients with chronic hepatitis B? [J]. Journal of Practical Hepatology, 2023, 26(2): 181-184.
[3]	Zhang Longyu, Mou Danlei, Li Tongzeng, et al.. Clinical efficacy of granulocyte colony stimulating factor in the treatment of patients with severe alcoholic hepatitis:a Meta-analysis [J]. Journal of Practical Hepatology, 2023, 26(2): 210-213.
[4]	Wang Yan, Zhou Jing, Han Jun. Clinicopathological features of patients with autoimmune hepatitis and drug-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(2): 218-221.
[5]	Dou Jing, Xu Qiang, Wang Zhuanguo, et al.. Clinical and liver histopathological features of patients with autoimmune hepatitis with low serum IgG and normal alanine aminotransferase levels [J]. Journal of Practical Hepatology, 2023, 26(2): 222-225.
[6]	Li Yanfen, Zhang Xiaowen, Wang Yanru, et al.. Rescuing therapy of obeticholic acid and fibrates in patients with primary biliary cholangitis without complete response to ursodeoxycholic acid treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 226-229.
[7]	Xu Jing, Liu Kun, Ma Zhufang. Clinical efficacy of magnesium isoglycyrrhizinate in preventing and treating liver and kidney injuries in patients with advanced gastric cancer undergoing chemotherapy [J]. Journal of Practical Hepatology, 2023, 26(2): 234-237.
[8]	Cheng Xiaoyan, Zhao Aiming, Li Haidan, et al.. Distribution of pathogens and serum Th1/Th2 cytokine changes in patients with hepatitis B virus related acute-on-chronic liver failure and nosocomial infections [J]. Journal of Practical Hepatology, 2023, 26(2): 246-249.
[9]	Cheng Yang, Zhang Feng, Wang Xixuan, et al.. Comparison of clinical efficacy of carvedilol and propranolol in preventing esophagogastric varices bleeding in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(2): 254-257.
[10]	Zhang Bin, Zhao Yuliang, Yan Guobei. Efficacy of hUCB-MNC and hUC-MSC transfusion in patients with decompensated hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(2): 262-265.
[11]	Zhou Qiujuan, Zhu Yiming, Ma Yuhang, et al.. Improvement of hypersplenism in patients hepatitis B cirrhosis after TIPS and PSE combination treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 266-269.
[12]	Gu Kai, Wu Xiaochen, Zhu Yiming. Single high dose of hepatic irradiation in ameliorating hepatic pain in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(2): 270-273.
[13]	Gong Cheng, Tian Yinsheng, Liu Shuang. Comparison of two-year survivals in primary liver cancer patients with spontaneous tumor rupture underwent hepatectomy at early or late operation time windows [J]. Journal of Practical Hepatology, 2023, 26(2): 274-277.
[14]	Shi Hao, Chen Yong, Luo Bin, et al.. Preoperative doxorubicin magnetic fluid targeted chemotherapy before microwave ablation in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(2): 278-281.
[15]	Yin Qiushi, Wang Xueguo, Song Qifeng. Comparison of complete laparoscopic left hemihepatectomy and traditional open laparotomy with left hepatic pedicle occlusion in treatment of patients with intrahepatic and extrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2023, 26(2): 282-285.